Deconstruction of the SS18-SSX Fusion Oncoprotein Complex: Insights into Disease Etiology and Therapeutics
- 1 March 2012
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 21 (3) , 333-347
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (K08CA138764)
- National Cancer Institute (SB939)
- Canadian Cancer Society Research Institute (018355)
- Arthritis Society
- Terry Fox Foundation
This publication has 43 references indexed in Scilit:
- Immunohistochemical Staining for TLE1 Distinguishes Synovial Sarcoma From Histologic MimicsAmerican Journal of Clinical Pathology, 2011
- Small blue round cell tumor of the interosseous membrane bearing a t(2;22)(q34;q12)/EWS-CREB1 translocation: a case reportMolecular Cytogenetics, 2010
- Transcriptional corepressor TLE1 functions with Runx2 in epigenetic repression of ribosomal RNA genesProceedings of the National Academy of Sciences, 2010
- Histone Deacetylase Inhibitors Reverse SS18-SSX–Mediated Polycomb Silencing of the Tumor Suppressor Early Growth Response 1 in Synovial SarcomaCancer Research, 2008
- The SYT-SSX Fusion Protein Down-Regulates the Cell Proliferation Regulator COM1 in t(x;18) Synovial SarcomaMolecular and Cellular Biology, 2007
- Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivoCancer Letters, 2005
- Molecular characterisation of soft tissue tumours: a gene expression studyThe Lancet, 2002
- Fusions of the SYT and SSX genes in synovial sarcomaOncogene, 2001
- ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylationNature, 2000
- A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomasOncogene, 1998